TVTX Relative Valuation
TVTX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, TVTX is overvalued; if below, it's undervalued.
Historical Valuation
Travere Therapeutics Inc (TVTX) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of 37.40. The fair price of Travere Therapeutics Inc (TVTX) is between NaN to NaN according to relative valuation methord.
Relative Value
Fair Zone
NaN-NaN
Current Price：34.85
Fair
35.21
PE
1Y
3Y
5Y
Trailing
Forward
16.21
EV/EBITDA
Travere Therapeutics Inc. (TVTX) has a current EV/EBITDA of 16.21. The 5-year average EV/EBITDA is 11.83. The thresholds are as follows: Strongly Undervalued below -137.06, Undervalued between -137.06 and -62.61, Fairly Valued between 86.28 and -62.61, Overvalued between 86.28 and 160.73, and Strongly Overvalued above 160.73. The current Forward EV/EBITDA of 16.21 falls within the Historic Trend Line -Fairly Valued range.
-162.57
EV/EBIT
Travere Therapeutics Inc. (TVTX) has a current EV/EBIT of -162.57. The 5-year average EV/EBIT is -13.13. The thresholds are as follows: Strongly Undervalued below -68.13, Undervalued between -68.13 and -40.63, Fairly Valued between 14.37 and -40.63, Overvalued between 14.37 and 41.87, and Strongly Overvalued above 41.87. The current Forward EV/EBIT of -162.57 falls within the Strongly Undervalued range.
5.20
PS
Travere Therapeutics Inc. (TVTX) has a current PS of 5.20. The 5-year average PS is 5.33. The thresholds are as follows: Strongly Undervalued below 1.38, Undervalued between 1.38 and 3.36, Fairly Valued between 7.30 and 3.36, Overvalued between 7.30 and 9.28, and Strongly Overvalued above 9.28. The current Forward PS of 5.20 falls within the Historic Trend Line -Fairly Valued range.
55.19
P/OCF
Travere Therapeutics Inc. (TVTX) has a current P/OCF of 55.19. The 5-year average P/OCF is -8.58. The thresholds are as follows: Strongly Undervalued below -36.92, Undervalued between -36.92 and -22.75, Fairly Valued between 5.59 and -22.75, Overvalued between 5.59 and 19.76, and Strongly Overvalued above 19.76. The current Forward P/OCF of 55.19 falls within the Strongly Overvalued range.
94.85
P/FCF
Travere Therapeutics Inc. (TVTX) has a current P/FCF of 94.85. The 5-year average P/FCF is -0.82. The thresholds are as follows: Strongly Undervalued below -50.66, Undervalued between -50.66 and -25.74, Fairly Valued between 24.10 and -25.74, Overvalued between 24.10 and 49.02, and Strongly Overvalued above 49.02. The current Forward P/FCF of 94.85 falls within the Strongly Overvalued range.
Travere Therapeutics Inc (TVTX) has a current Price-to-Book (P/B) ratio of 42.38. Compared to its 3-year average P/B ratio of 16.61 , the current P/B ratio is approximately 155.07% higher. Relative to its 5-year average P/B ratio of 12.59, the current P/B ratio is about 236.60% higher. Travere Therapeutics Inc (TVTX) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -25.70%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -16.75% , the current FCF yield is about -100.00% lower.
42.96
P/B
Median3y
16.61
Median5y
12.59
-1.89
FCF Yield
Median3y
-25.70
Median5y
-16.75
Competitors Valuation Multiple
The average P/S ratio for TVTX's competitors is , providing a benchmark for relative valuation. Travere Therapeutics Inc Corp (TVTX) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of 162.11%, this premium appears sustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of TVTX increased by 102.81% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 62.90M to 164.86M.
The secondary factor is the P/E Change, contributed 58.61%to the performance.
Overall, the performance of TVTX in the past 1 year is driven by Revenue Growth. Which is more sustainable.
People Also Watch
FAQ
Is Travere Therapeutics Inc (TVTX) currently overvalued or undervalued?
What is Travere Therapeutics Inc (TVTX) fair value?
How does TVTX's valuation metrics compare to the industry average?
What is the current P/B ratio for Travere Therapeutics Inc (TVTX) as of Dec 05 2025?
What is the current FCF Yield for Travere Therapeutics Inc (TVTX) as of Dec 05 2025?
What is the current Forward P/E ratio for Travere Therapeutics Inc (TVTX) as of Dec 05 2025?